Back

Poster Presentations: AASLD Liver Meeting 2017

At the AASLD Liver Meeting this year, the following presentations were conducted by our distinguished partner and collaborator respectively:

Detailed Analysis of the Antifibrotic Effect of INT-767, a Dual FXR/TGR5 Agonist in an Obese Mouse Model of Diet-induced and Biopsy-confirmed NASH

By Dr Mathieu Petitjean, CEO, MedNest, USA

The farnesoid X receptor (FXR) and G protein coupled receptor (GPCR) TGR5 have been implicated in the regulation of metabolism, inflammation and fibrosis in non-alcoholic steatohepatitis (NASH). A dual FXR/TGR5 agonist, INT-767, has been developed and is in early clinical development. 

Application of Human NASH-based Transcriptome and Metabolome Profiles in Preclinical Models

By Dr Martine Morrison, TNO, Metabolic Health Research, The Netherlands

Dr. Morrison presented on the representation of human-based molecular disease profiles in an established pre-clinical model for NASH research - the Ldlr-/-.Leiden mouse – and the translational value of this model for the study of NASH-associated hepatic fibrosis.

Back

Our site uses cookies or similar technologies to recognise your repeated visits and preferences for us to deliver an optimal browsing experience. Please remember to read our privacy statement.

By clicking on "I Accept" or "X" to continue your browsing on this site, you consent to the use of the cookies. To find out how you can disable cookies on your device, please click here.

I Accept